




# Company Non Confidential Information

# Company Origin

2009



Poxel

Product development program  
and R&D portfolio management

## About Poxel (11 March 2009)

- A diabetes drug development specialist located in Lyon (France) that aims at progressing promising assets for **Type 2 diabetes** up to phase II clinical proof of concept, before partnering to pharmaceuticals companies
- Pharmaceutical partners to be responsible for late clinical development and commercialization stages
- A spin-off from Merck Serono that owns intellectual property of its products
- A company operating completely independently as a lean organization with a strong in-house drug development expertise
- July 2010: Poxel raised €16 million in a Series A financing to accelerate its pipeline development

# Market & Products

Strong and sustained growth of the T2DM market:

- 2009: \$20,5bio => 2019: \$ 36,2bio
- Growth factors: age, obesity, new products (DPPIV inhibitors, GLP1 agonists), improvement of diagnosis and drug treatment
- Constraints: key generic products, regulatory hurdles, payers pressure

Poxel products (small molecules) target metabolic diseases, providing:


- An innovative and disease modifying mechanism of action
- A combined activity on glucose metabolism and other cardiovascular risk factors
- An improved safety profile compared to currently available therapies

# A Seasoned Management Team

## From Research to Business Development

- **An integrated strategic and operational view of the product value chain , covering the product life cycle**
  - Research
  - Development
  - Marketing
  - Business Development
  - Finance
- **More than 10 years expertise in Pharma/Industry environment for each individual**
  - Involved in CardioMetabolic operations
  - Most employees have been involved in Imeglimin development at Merck Serono from Research to Development to Marketing and Business Development
  - A broad network in the Diabetes world and in the Pharma environment (KOL, Regulatory, Business Development, Top management)
  - Expertise and experience in M&A

# Business Model








Imeglimin

# Imeglimin Key Facts



- **The first** in a new tetrahydrotriazine-containing class of oral anti-diabetic agents: the Glimins
- **An original mode of action**, targeting the 3 key defects of T2DM, in:
  - decreasing hepatic glucose production
  - increasing muscle glucose uptake
  - increasing glucose-dependent insulin secretion
- **An excellent efficacy and safety/tolerability profile**, already demonstrated in 4 phase I and 2 phase II trials
- **A very safe profile in renal impaired patients**, allowing its prescription in mild, moderate and severe stages (with dose adaptation)
- **A real potential in combination** with main oral anti-diabetics: subject to ongoing trials

# Imeglimin Key Results

Change in AUC glucose in naïve (plain) and previously treated subjects (hatching)



Change in HbA1c from baseline to end of treatment depending on baseline HbA1c



**EASD 2010 poster:**  
*Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in Type 2 diabetic patients*  
 V. Pirags (Latvia), H. Lebovitz (USA), and P. Fouqueray (Fr)



# AMPK Activators

# Direct AMPK Activators

## Development Rationale

- Compounds increasing 5' AMP-activated protein kinase (AMPK) activity normalize glycemia and the lipid profile by:
  - ↗ glucose uptake (independently of insulin)
  - ↗ lipid oxidation
  - ↘ glucose and lipid production
- **A selective and direct AMPK activation induces a greater benefit** on the diabetes and dyslipidemic profile compared to an indirect and non selective activation
- Particularly adapted to T2DM patients with **cardiovascular complications**
- **Development candidate identification ongoing**



**Head Office:**  
200 avenue Jean Jaurès  
69007 Lyon  
France

Tel: +33 4 37 37 20 10  
Fax: +33 4 37 70 88 15

[contact@poxelpharma.com](mailto:contact@poxelpharma.com)

[www.poxel.com](http://www.poxel.com)